{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T18:34:26Z","timestamp":1789929266642,"version":"4.0.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":562,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.jval.2011.08.1741","type":"journal-article","created":{"date-parts":[[2011,11,13]],"date-time":"2011-11-13T20:54:57Z","timestamp":1321217697000},"page":"55-64","source":"Crossref","is-referenced-by-count":12,"title":["Updating and Confirming an Industry-Sponsored Pharmacoeconomic Model: Comparing Two Antipsychotics in the Treatment of Schizophrenia"],"prefix":"10.1016","volume":"15","author":[{"given":"Christopher N.","family":"Graham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine A.","family":"Mauskopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony H.","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haya","family":"Ascher-Svanum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bruhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2011.08.1741_bib1","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1192\/bjp.183.6.498","article-title":"Quantitative analysis of sponsorship bias in economic studies of antidepressants","volume":"183","author":"Baker","year":"2003","journal-title":"Br J Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.jval.2011.08.1741_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1331.2005.01202.x","article-title":"Cost of disorders of the brain in Europe","volume":"12","author":"Andlin-Sobocki","year":"2005","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jval.2011.08.1741_bib3","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.4088\/JCP.v66n0906","article-title":"The economic burden of schizophrenia in the United States in 2002","volume":"66","author":"Wu","year":"2005","journal-title":"J Clin Psychiatry"},{"issue":"2, Suppl.","key":"10.1016\/j.jval.2011.08.1741_bib4","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"Lehman","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jval.2011.08.1741_bib5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3111\/200104179192","article-title":"Comparing olanzapine and ziprasidone in the treatment of schizophrenia: a case study in modeling","volume":"4","author":"Alexeyeva","year":"2001","journal-title":"J Med Econ"},{"key":"10.1016\/j.jval.2011.08.1741_bib6","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0149-2918(97)80140-3","article-title":"Pharmacoeconomic applications of meta-analysis for single groups using antifungal onychomycosis lacquers as an example","volume":"19","author":"Einarson","year":"1997","journal-title":"Clin Ther"},{"key":"10.1016\/j.jval.2011.08.1741_bib7","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1176\/appi.ajp.162.10.1879","article-title":"Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia","volume":"162","author":"Breier","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jval.2011.08.1741_bib8","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s00213-003-1652-2","article-title":"Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder","volume":"172","author":"Harvey","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jval.2011.08.1741_bib9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1176\/jnp.18.1.54","article-title":"Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine","volume":"18","author":"Harvey","year":"2006","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.jval.2011.08.1741_bib10","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2011.08.1741_bib11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.jcp.0000204137.82298.06","article-title":"A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms","volume":"26","author":"Kinon","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jval.2011.08.1741_bib12","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2011.08.1741_bib13","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1192\/bjp.bp.105.019307","article-title":"Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia","volume":"189","author":"McCue","year":"2006","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jval.2011.08.1741_bib14","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1176\/appi.ajp.161.10.1837","article-title":"Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder","volume":"161","author":"Simpson","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jval.2011.08.1741_bib15","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1176\/appi.ajp.162.8.1535","article-title":"Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia","volume":"162","author":"Simpson","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jval.2011.08.1741_bib16","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/ajp.2006.163.4.611","article-title":"Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic","volume":"163","author":"Stroup","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jval.2011.08.1741_bib17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0924-977X(96)00392-6","article-title":"Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial","volume":"7","author":"Beasley","year":"1997","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.jval.2011.08.1741_bib18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s002130050755","article-title":"Ziprasidone 40 and 120 mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial","volume":"140","author":"Keck","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jval.2011.08.1741_bib19","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/oxfordjournals.schbul.a006969","article-title":"Estimating the costs and benefits of new drug therapies: atypical antipsychotic drugs for schizophrenia","volume":"28","author":"Mauskopf","year":"2002","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.jval.2011.08.1741_bib20","first-page":"345","article-title":"A cost-effectiveness clinical decision analysis model for schizophrenia","volume":"4","author":"Palmer","year":"1998","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jval.2011.08.1741_bib21","series-title":"The Essential RBRVS: A Comprehensive Listing of RBRVS Values for CPT and HCPCS Codes","year":"2008"},{"key":"10.1016\/j.jval.2011.08.1741_bib23","series-title":"Trends in Psychiatric Health Systems: 1995 Annual Survey, Final Report","year":"1995"},{"key":"10.1016\/j.jval.2011.08.1741_bib24","first-page":"1","article-title":"Fee, practice and managed care survey","volume":"21","year":"1995","journal-title":"Psychother Finances"},{"key":"10.1016\/j.jval.2011.08.1741_bib25","series-title":"Red Book for Windows [computer program]","year":"2010"},{"key":"10.1016\/j.jval.2011.08.1741_bib26","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1192\/bjp.172.6.499","article-title":"Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses","volume":"172","author":"Tran","year":"1998","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jval.2011.08.1741_bib27","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1176\/appi.ajp.158.5.765","article-title":"A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder","volume":"158","author":"Conley","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jval.2011.08.1741_bib28","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.schres.2003.10.010","article-title":"Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative syndrome scales","volume":"71","author":"Lenert","year":"2004","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jval.2011.08.1741_bib29","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pnpbp.2003.09.033","article-title":"Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia","volume":"28","author":"Bitter","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.jval.2011.08.1741_bib30","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/aje\/kwj289","article-title":"Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia","volume":"164","author":"Lambert","year":"2006","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jval.2011.08.1741_bib31","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1192\/bjp.bp.107.037184","article-title":"First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis","volume":"192","author":"Smith","year":"2008","journal-title":"Br J Psychiatry>"},{"key":"10.1016\/j.jval.2011.08.1741_bib32","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/pds.1781","article-title":"The incidence of diabetes in atypical antipsychotic users differs according to agent---results from a multisite epidemiologic study","volume":"18","author":"Yood","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jval.2011.08.1741_bib33","first-page":"11","article-title":"Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event Database: a systematic Bayesian signal detection analysis","volume":"42","author":"Baker","year":"2009","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.jval.2011.08.1741_bib34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1477-7525-6-105","article-title":"Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation","volume":"6","author":"Briggs","year":"2008","journal-title":"Health Qual Life Outcomes"},{"issue":"Suppl.","key":"10.1016\/j.jval.2011.08.1741_bib35","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.schres.2007.12.377","article-title":"Comparative mortality associated with ziprasidone vs olanzapine in real-world use: the ziprasidone observational study of cardiac outcomes (ZODIAC) [abstract]","volume":"98","author":"Strom","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jval.2011.08.1741_bib36","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1176\/appi.ps.56.7.803","article-title":"Pharmacotherapy and health care costs among patients with schizophrenia and newly diagnosed diabetes","volume":"56","author":"Leslie","year":"2005","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.jval.2011.08.1741_bib37","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1478-7547-7-4","article-title":"Cost-effectiveness model comparing olanzapine and other atypical antipsychotics in the treatment of schizophrenia in the United States","volume":"7","author":"Furiak","year":"2009","journal-title":"Cost Eff Resour Alloc"},{"key":"10.1016\/j.jval.2011.08.1741_bib38","series-title":"Overview of Atypical Antipsychotic Monotherapy for Schizophrenia: Clinical Review and Economic Evaluation of First Year of Treatment [Technology overview number 32]","author":"Farahati","year":"2007"},{"key":"10.1016\/j.jval.2011.08.1741_bib39","series-title":"Briefing Document for Zeldox Capsules (Ziprasidone HCl)","year":"2000"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301511033389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301511033389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T11:23:54Z","timestamp":1543404234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301511033389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S1098301511033389"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2011.08.1741","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}